Resolution Therapeutics reported interim six-month data from the Phase I/II EMERALD trial of RTX001, an autologous macrophage therapy engineered with mRNA encoding IL-10 and MMP-9, in end-stage liver disease. Among the first nine of 15 treated patients compared with 21 external standard-of-care controls, the composite endpoint of death, transplant or hepatic decompensation was reduced by 42 percent in relative terms, with no treatment-related severe adverse events. Biomarker analyses showed lower inflammatory pathway activity and reduced markers of fibrogenesis.
Key Points
- 42% relative risk reduction in death, transplant or decompensation
- Engineered macrophages deliver IL-10 and MMP-9 via mRNA
- Biomarkers showed reduced inflammation and fibrogenesis; no severe treatment-related events
Longevity Analysis
Fibrosis is the common endpoint of chronic injury across most organs, and the liver is the clearest testing ground for reversing it rather than slowing it. Reprogramming the body's own clearance cells to resolve scar tissue and dampen inflammatory signaling targets the mechanism, not the symptom — an approach with implications well beyond hepatology, given that the liver governs chemical clearance for every other system. The small sample, external control design and 2028 primary analysis keep this firmly in the early-signal category, but the biomarker shifts suggest the intended biology is engaging.
Original published by Longevity.Technology.